Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genes.

IF 7.6 2区 医学 Q1 ONCOLOGY
Christopher J Schwartz, Iskender Genco, Matteo Repetto, Daniel Muldoon, Andrea Gazzo, Panieh Terraf, Anne Grabenstetter, Dara Ross, Hong Zhang, Diana Mandelker, Simon Powell, Britta Weigelt, Chaitanya Bandlamudi, Edi Brogi, Fresia Pareja, Hannah Y Wen
{"title":"Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genes.","authors":"Christopher J Schwartz, Iskender Genco, Matteo Repetto, Daniel Muldoon, Andrea Gazzo, Panieh Terraf, Anne Grabenstetter, Dara Ross, Hong Zhang, Diana Mandelker, Simon Powell, Britta Weigelt, Chaitanya Bandlamudi, Edi Brogi, Fresia Pareja, Hannah Y Wen","doi":"10.1038/s41523-025-00794-z","DOIUrl":null,"url":null,"abstract":"<p><p>Invasive breast carcinomas associated with microglandular adenosis (IBC-MGA) represent a rare and poorly characterized form of triple-negative breast cancer (TNBC). We analyzed clinical, pathological, and germline genetic data from 38 patients, including 34 IBC-MGAs and 4 in situ cases. Germline pathogenic or likely pathogenic variants in homologous recombination-deficiency (HRD) genes were found in 42% (16/38) of patients, predominantly in BRCA1 (81%, 13/16). Most tumors were grade 3 invasive ductal or metaplastic carcinomas with limited tumor-infiltrating lymphocytes. No significant clinicopathologic differences were observed between germline HRD-associated and sporadic cases. Paired tumor-normal targeted sequencing revealed frequent TP53 mutations and high HRD scores. These findings underscore the relationship of breast carcinomas associated with MGA with HRD-related germline variants and highlight the potential for targeted therapeutic strategies and the importance of genetic testing in this rare subset of TNBC.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"76"},"PeriodicalIF":7.6000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12280099/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-025-00794-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Invasive breast carcinomas associated with microglandular adenosis (IBC-MGA) represent a rare and poorly characterized form of triple-negative breast cancer (TNBC). We analyzed clinical, pathological, and germline genetic data from 38 patients, including 34 IBC-MGAs and 4 in situ cases. Germline pathogenic or likely pathogenic variants in homologous recombination-deficiency (HRD) genes were found in 42% (16/38) of patients, predominantly in BRCA1 (81%, 13/16). Most tumors were grade 3 invasive ductal or metaplastic carcinomas with limited tumor-infiltrating lymphocytes. No significant clinicopathologic differences were observed between germline HRD-associated and sporadic cases. Paired tumor-normal targeted sequencing revealed frequent TP53 mutations and high HRD scores. These findings underscore the relationship of breast carcinomas associated with MGA with HRD-related germline variants and highlight the potential for targeted therapeutic strategies and the importance of genetic testing in this rare subset of TNBC.

Abstract Image

Abstract Image

与微腺腺病相关的乳腺癌与同源重组缺陷基因的种系改变有关。
浸润性乳腺癌伴微腺腺病(IBC-MGA)是一种罕见且特征不明确的三阴性乳腺癌(TNBC)。我们分析了38例患者的临床、病理和种系遗传数据,其中包括34例IBC-MGAs和4例原位病例。在42%(16/38)的患者中发现同源重组缺陷(HRD)基因的种系致病性或可能致病性变异,主要是BRCA1基因(81%,13/16)。大多数肿瘤为3级浸润性导管癌或化生癌,肿瘤浸润淋巴细胞有限。生殖系hrd相关病例和散发病例之间没有明显的临床病理差异。配对肿瘤正常靶向测序显示TP53突变频繁,HRD评分高。这些发现强调了与MGA相关的乳腺癌与hrd相关的生殖系变异的关系,并强调了靶向治疗策略的潜力以及在这种罕见的TNBC亚群中进行基因检测的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
NPJ Breast Cancer
NPJ Breast Cancer Medicine-Pharmacology (medical)
CiteScore
10.10
自引率
1.70%
发文量
122
审稿时长
9 weeks
期刊介绍: npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信